Oncology

AbbVie and Jacobio Enter Strategic Collaboration to Advance SHP2 Inhibitors

NORTH CHICAGO, Ill. and BEIJING, June 1, 2020 /PRNewswire/ — AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, and Jacobio Pharmaceuticals, a clinical-stage pharmaceutical company, today announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 is an important protein mediator of cellular signaling through RAS/MAP kinase …

Read More »

Lilly’s Cyramza Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

INDIANAPOLIS, May 29, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), in combination with erlotinib, for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or …

Read More »

Pfizer Provides Update on Phase 3 Trial of Ibrance Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer

NEW YORK–(BUSINESS WIRE)–As announced today by the Austrian Breast & Colorectal Cancer Study Group and the Alliance Foundation Trials, LLC, Pfizer Inc. (NYSE: PFE) reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase 3 early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined …

Read More »

FDA Approves Genentech’s Tecentriq in Combination with Avastin for Treatment of Advanced Hepatocellular Carcinoma

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior …

Read More »

Final Results from Phase 3 Study Show Xtandi Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer

NEW YORK and TOKYO, May 29, 2020 /PRNewswire/ — Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) have announced final results from the overall survival (OS) analysis of the Phase 3 PROSPER trial, which evaluated XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) …

Read More »

Cardiff Oncology Announces FDA Grants Fast Track Designation to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

SAN DIEGO, May 28, 2020 /PRNewswire/ — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, Zytiga®-resistant prostate cancer and leukemia, today announced that the U.S. Food and Drug Administration (FDA) …

Read More »

Daiichi Sankyo and Syneos Health Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline

BASKING RIDGE, N.J. & MORRISVILLE, N.C.–(BUSINESS WIRE)–Daiichi Sankyo, Inc. (hereafter, Daiichi Sankyo) announced that it has entered into a strategic agreement with Syneos Health® (Nasdaq:SYNH). The companies are coming together to form a coalition to accomplish their shared goal of bringing promising cancer therapies to patients as safely, effectively and efficiently as …

Read More »

Gilead Enters into a $2 Billion Deal with Arcus Focused on Next-Generation Cancer Immunotherapies

FOSTER CITY, Calif. & HAYWARD, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today that the companies have entered into a 10-year partnership to co-develop and co-commercialize current and future therapeutic product candidates in Arcus’s …

Read More »

FDA Approves Opdivo + Yervoy Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent NSCLC

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with metastatic or recurrent non-small cell lung cancer …

Read More »

Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in …

Read More »